AESTHETICS


effects. These are usually as a result of inappropriate injection of the toxin into muscle groups adjacent to the injection site (although there have been cases of toxicity to the practitioner, due to needlestick injuries)8


.


The symptoms of toxicity include paralysis of critical muscle groups and may involve arrhythmia, and in some cases, seizures, respiratory arrest, and death9


clinical experience7 .


COSMETIC USE OF BOTULINUM TOXIN


. Specifi c side effects associated with cosmetic use may include muscle weakness, dysphagia (diffi culty swallowing food), allergic reactions, and fl u-like syndromes9


.


A further clinical complication is that commercial preparations from different manufacturers may contain variants of the toxin which have been purifi ed or formulated differently, meaning they are unlikely to exhibit equivalent bioavailability. Required dosage should be calculated independently for each preparation, based on previous response and


In addition to its established medical use for the relief of excessive muscle tone, Botulinum toxin is increasingly being used for cosmetic applications. Injection of the toxin into facial muscles (particularly the upper third of the face) results in paralysis of these muscles and gives the appearance of fewer wrinkles around the eyes and forehead. As with licensed medical use, the treatment wears off within a few months and repeated injections are required to maintain the ‘youthful’ appearance10,11


. Excessive use of


Botulinum toxin injection may lead to the face becoming ‘mask-like’ with the patient unable to move their eyebrows or register surprise11


. TREATMENT BY PHARMACISTS


As discussed above, Botulinum toxin is a spectacularly toxic substance and great care should be taken


BOTOX: THE POSITIVE MEDICAL EFFECTS


Did you know that, in addition to its ‘cosmetic’ qualities, Botox has also been proven to provide positive medical effects in the treatment of migraines, excessive sweating, overactive bladder and depression?


Stephen McCoy, who was critically injured in the Kegworth air disaster in 1989, and who is now paralysed down one side of his body, receives Botox injections in his left hand every four or fi ve months. His sister,


when handling or administering the material. Currently, administration for medical purposes is undertaken by physicians specialising in orthopedics or paediatrics, plastic surgeons, or by suitably trained nurse practitioners.


Pharmacists are the acknowledged experts in drugs and medicines and have been trained throughout their four years at university and their one year pre-registration experience to handle potent and toxic materials safely. It is therefore appropriate for pharmacists to use this training and experience to administer Botulinum toxin to patients for cosmetic procedures. Suitable premises will be required ensuring patient privacy and confi dentiality, but if these requirements are met, this author sees no diffi culty with pharmacists becoming Botox practitioners. Indeed, many pharmacists are now qualifi ed Independent Prescribers, and are well-placed to prescribe analgesics or topical therapy to treat local pain or infl ammation at the site of injection. •


Yvonne, who cares for him, says that the benefi ts that Stephen gains from the injections far outweigh any down sides.


‘Botox was fi rst suggested to us about three years ago by Dr McDonald from Musgrave Park Hospital,’ Yvonne tells SP. ‘Since Stephen is paralysed down his left side, it is up to me to keep his hand and nails clean to avoid any infection. This has on occasion proved very diffi cult as his hand is in a clenched position, with his nails often ‘dug’ into his hand.


‘Stephen now receives Botox injections into this hand and this ensures that his hand remains relaxed and ‘loose’, enabling me to cut his nails and keep his hand nice and fresh. The injection itself is painful – even though Stephen has no real feeling in the hand – but there’s no doubt that the benefi ts that the Botox brings to him – and me – far outweigh the pain or any down side. For a few days after the injection he has to wear a splint, but without it, I wouldn’t be able to ensure that I could keep his hand infection free.’


56 - SCOTTISH PHARMACIST REFERENCES


1.Molenaers, G; Van Campenhout, A; Fagard, K; De Cat, Jos and Desloovere, K. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J. Child. Orthop. 2010, Jun; 4(3): 183–195.


2. Weller C (15 October 2013). “New Botulinum Toxin Deemed Deadliest Substance Ever: Sniffi ng 13-Billionths Of A Gram Can Kill”. Medical Daily.


3. Walsh S (October 15, 2010). “FDA approves Botox to treat chronic migraine”. FDA Press Releases. Retrieved October 15, 2010.


4 Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM (December 2000). “Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study”. Otolaryngology—Head and Neck Surgery. 123 (6): 669–76. doi:10.1067/ mhn.2000.110960. PMID 11112955.


5. Walker TJ, Dayan SH (February 2014). “Comparison and overview of currently available neurotoxins”. The Journal of Clinical and Aesthetic Dermatology. 7 (2): 31–39. PMC 3935649 . PMID 24587850.


6. Montecucco C, Molgó J (June 2005). “Botulinal neurotoxins: revival of an old killer”. Current Opinion in Pharmacology. 5 (3): 274–79. doi:10.1016/j.coph.2004.12.006. PMID 15907915.


7. Felber ES (October 2006). “Botulinum toxin in primary care medicine”. The Journal of the American Osteopathic Association. 106 (10): 609–14. PMID 17122031.


8. Wicker, S; Ludwig, A; Gottschalk, R; Rabenau, HF (2008). “Needlestick injuries among health care workers: Occupational hazard or avoidable hazard?”. Wiener klinische Wochenschrift. 120: 486–92. doi:10.1007/s00508-008-1011-8. PMID 18820853.


9. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM (September 2005). “Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases”. Journal of the American Academy of Dermatology. 53 (3): 407–15.


10. Carruthers JD, Carruthers JA (January 1992). “Treatment of glabellar frown lines with C. botulinum-A exotoxin”. The Journal of Dermatologic Surgery and Oncology. 18 (1): 17–21. doi:10.1111/j.1524-4725.1992.tb03295.x. PMID


11 Keen M, Kopelman JE, Aviv JE, Binder W, Brin M, Blitzer A (April 1994). “Botulinum toxin A: a novel method to remove periorbital wrinkles”. Facial Plastic Surgery. Thieme Medical Publishers. 10 (2): 141–46. doi:10.1055/s-2008-1064563. PMID 7995530.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64